^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PDE4 inhibitor

    Related drugs:
    27d
    A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD (clinicaltrials.gov)
    P3, N=387, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    1m
    A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder (clinicaltrials.gov)
    P2, N=195, Completed, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Completed
    Trial completion
    1m
    Hemay005 for the Treatment of Chinese Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov)
    P3, N=360, Not yet recruiting, Ganzhou Hemay Pharmaceutical Co., Ltd
    New P3 trial
    1m
    A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment of COPD (clinicaltrials.gov)
    P3, N=376, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    1m
    A Clinical Trial to Evaluate the Efficacy and Safety of HRS-9821 Inhalation Suspension in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Guangdong Hengrui Pharmaceutical Co., Ltd
    New P2 trial
    1m
    An Open-label, Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Cutaneous Adverse Events Due to Checkpoint Inhibitors (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Massachusetts General Hospital
    New P2 trial • Adverse events • Checkpoint inhibition
    1m
    Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler and HSK39004 Inhalation Suspension in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov)
    P2, N=50, Recruiting, Haisco Pharmaceutical Group Co., Ltd. | Active, not recruiting --> Recruiting
    Enrollment open
    1m
    Effect of Roflumilast as Add-On Therapy in Rheumatoid Arthritis (clinicaltrials.gov)
    P2, N=50, Recruiting, Horus University
    New P2 trial
    |
    roflumilast
    1m
    Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Haisco Pharmaceutical Group Co., Ltd.
    New P3 trial
    2ms
    Roflumilast prevented tissue damage caused by lipopolysaccharide-induced sepsis via anti-inflammatory action. (PubMed, PLoS One)
    While 1.5 mg/kg Roflumilast showed no protective effects, 3 mg/kg markedly reduced inflammatory and injury markers, improved tissue architecture, and decreased KIM-1 expression. These findings suggest that a higher dose of Roflumilast effectively mitigates LPS-induced systemic inflammation and organ injury, supporting its potential as a therapeutic option for sepsis.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • KIM1 (Kidney injury molecule 1) • IL1B (Interleukin 1, beta)
    |
    roflumilast
    2ms
    TAM-AMIN-UAS: Tamsulosin and Intraureteral Aminophylline for Ureteral Access During RIRS (clinicaltrials.gov)
    P2, N=322, Recruiting, Beni-Suef University
    New P2 trial
    2ms
    Intravesical Aminophylline for Urgent Ureteral Stenting in Acute Calculous Anuria (clinicaltrials.gov)
    P2, N=72, Recruiting, Beni-Suef University
    New P2 trial